Alterity Therapeutics Limited
PRNAF
$0.0101
$0.0065180.56%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 523.20K | 538.00K | 698.00K | 696.60K | 619.40K |
| Total Revenue | 523.20K | 538.00K | 698.00K | 696.60K | 619.40K |
| Cost of Revenue | 20.70K | 21.30K | 38.70K | 38.60K | 31.60K |
| Gross Profit | 502.50K | 516.70K | 659.40K | 658.00K | 587.80K |
| SG&A Expenses | 1.08M | 1.11M | 890.10K | 888.30K | 671.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 18.40K | 18.90K | 500.00 | 500.00 | 1.20K |
| Total Operating Expenses | 2.98M | 3.07M | 4.98M | 4.97M | 2.78M |
| Operating Income | -2.46M | -2.53M | -4.28M | -4.27M | -2.16M |
| Income Before Tax | -2.34M | -2.40M | -4.14M | -4.13M | -2.12M |
| Income Tax Expenses | -- | -- | 15.20K | 15.20K | -- |
| Earnings from Continuing Operations | -2.34M | -2.40M | -4.16M | -4.15M | -2.12M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.34M | -2.40M | -4.16M | -4.15M | -2.12M |
| EBIT | -2.46M | -2.53M | -4.28M | -4.27M | -2.16M |
| EBITDA | -2.45M | -2.52M | -4.27M | -4.26M | -2.15M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 5.31B | 5.31B | 4.79B | 4.79B | 2.50B |
| Average Diluted Shares Outstanding | 5.31B | 5.31B | 4.79B | 4.79B | 2.50B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
